Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...

-- At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of Alzheimer's and all other dementia. -- The ...

Nearly 12 million family members and friends nationwide are serving as dementia caregivers, including more than 500,000 ...

“Choosing a meaningful gift for someone living with dementia requires thoughtful consideration,” said Stacie Kulp, executive director of the Alzheimer’s Association of Utah, in a written statement.

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically significant reduction in Alzheimer's ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...